Novo Nordisk transfers rights to an experimental Parkinson’s therapy to Cellular Intelligence, an AI startup backed by Mark Zuckerberg. Bloomberg reports that Novo agrees to hand over the therapy as a way to potentially accelerate its development. Gizmodo similarly states that Cellular Intelligence acquires the rights to the experimental Parkinson’s cell therapy from Novo, framing it as a shift away from the drugmaker that is known for therapies such as Ozempic.
Both outlets describe the arrangement as a transfer of development and related rights rather than an immediate launch of a new treatment. The sources do not provide additional clinical details such as trial phase, effectiveness results, timelines, or study locations. The reported deal centers on the use of Cellular Intelligence’s AI capabilities to advance the experimental program after it changes hands from Novo Nordisk.
